Atomo also said it has closed an oversubscribed initial public offering and that it intends to float its shares on the Australian Securities Exchange mid-month.
The device is designed to divert and isolate a small volume of the initial blood collected for culture, which is the portion most likely to contain contaminants.
The device is designed to stabilize RNA and DNA from fingerstick blood at room temperature for up to two weeks so that it can be mailed to a lab for analysis.
The specimen discard technology automatically and passively "sidelines" potential contaminants during the blood culture collection process, Kurin said.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
In the long term, the company is developing a plan to create more tests based on its technology, which digitizes blood samples and turns them into images.
Companies in the AMR space have met resistance from investors and clinicians as a result of conflicting hospital priorities and perceived technology shortcomings.
